Abstract
As the principal active ingredient in the Chinese herb Tripterygium wilfordii Hook.F (TwHF), triptolide has been shown to have very strong antitumor properties. The trimethylation of lysine 4 on histone H3 (H3K4me3) has been proposed to promote gene expression, and the accumulation of H3K4me3 at the transcriptional start sites of oncogenes is involved in carcinogenesis. To identify the association between the reduction of H3K4me3 and the apoptosis of MM cells induced by triptolide, we investigated the global patterns of H3K4me3 occupancy in the MM cell genome. Combined analyses using ChIP-on-chip and western blotting showed that H3K4me3 were highly enriched on the gene promoters of c-Myc and VEGFA and were associated with the up-regulation of both genes. Treatment of KM3 cells with triptolide and siRNA targeting ASH2L reduced the expression of c-Myc and VEGFA. These results suggest that triptolide can down-regulate c-Myc and VEGFA expression by blocking the accumulation of H3K4me3 on their promoters,and thus play an important role in anti-MM mechanism.
Keywords: Apoptosis, ASH2L, c-Myc, H3K4me3, Multiple myeloma, Triptolide, VEGFA.
Current Pharmaceutical Biotechnology
Title:Triptolide Induces Cell Apoptosis by Targeting H3K4me3 and Downstream Effector Proteins in KM3 Multiple Myeloma Cells
Volume: 17 Issue: 2
Author(s): Lu Wen, Yan Chen, Ling L. Zeng, Fei Zhao, Sha Yi, Li J. Yang, Ben P. Zhang, Jie Zhao, Zi C. Zhao and Chun Zhang
Affiliation:
Keywords: Apoptosis, ASH2L, c-Myc, H3K4me3, Multiple myeloma, Triptolide, VEGFA.
Abstract: As the principal active ingredient in the Chinese herb Tripterygium wilfordii Hook.F (TwHF), triptolide has been shown to have very strong antitumor properties. The trimethylation of lysine 4 on histone H3 (H3K4me3) has been proposed to promote gene expression, and the accumulation of H3K4me3 at the transcriptional start sites of oncogenes is involved in carcinogenesis. To identify the association between the reduction of H3K4me3 and the apoptosis of MM cells induced by triptolide, we investigated the global patterns of H3K4me3 occupancy in the MM cell genome. Combined analyses using ChIP-on-chip and western blotting showed that H3K4me3 were highly enriched on the gene promoters of c-Myc and VEGFA and were associated with the up-regulation of both genes. Treatment of KM3 cells with triptolide and siRNA targeting ASH2L reduced the expression of c-Myc and VEGFA. These results suggest that triptolide can down-regulate c-Myc and VEGFA expression by blocking the accumulation of H3K4me3 on their promoters,and thus play an important role in anti-MM mechanism.
Export Options
About this article
Cite this article as:
Wen Lu, Chen Yan, Zeng L. Ling, Zhao Fei, Yi Sha, Yang J. Li, Zhang P. Ben, Zhao Jie, Zhao C. Zi and Zhang Chun, Triptolide Induces Cell Apoptosis by Targeting H3K4me3 and Downstream Effector Proteins in KM3 Multiple Myeloma Cells, Current Pharmaceutical Biotechnology 2016; 17 (2) . https://dx.doi.org/10.2174/1389201016666150930115555
DOI https://dx.doi.org/10.2174/1389201016666150930115555 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protein Geranylgeranyltransferase Type 1 as a Target in Cancer
Current Cancer Drug Targets New Targets of Therapy in T-Cell Lymphomas
Current Drug Targets Immunotherapy of Malignant Gliomas Using Autologous and Allogeneic Tissue Cells
Anti-Cancer Agents in Medicinal Chemistry Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The History and Rationale for Monoclonal Antibodies in the Treatment of Hematologic Malignancy
Current Pharmaceutical Biotechnology Trends in the Treatment of Hepatocellular Carcinoma
Current Drug Therapy CD40L - A Multipotent Molecule for Tumor Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Stent-Based Delivered Anti-Proliferative Drugs in the Prevention of Coronary Stent Restenosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents ASPM Predicts Poor Clinical Outcome and Promotes Tumorigenesis for Diffuse Large B-cell Lymphoma
Current Cancer Drug Targets Difluorinated Curcumin: A Promising Curcumin Analogue with Improved Anti-Tumor Activity and Pharmacokinetic Profile
Current Pharmaceutical Design Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy
Current Pharmaceutical Design Zinc Complexes Developed as Metallopharmaceutics for Treating Diabetes Mellitus based on the Bio-Medicinal Inorganic Chemistry
Current Topics in Medicinal Chemistry Application of the Phage Display Technology for the Development of Peptide- mediated Drug Delivery Systems through the Blood-Brain Barrier
Current Pharmaceutical Biotechnology High-output Cardiac Failure: A Forgotten Phenotype in Clinical Practice
Current Cardiology Reviews Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Antifungal Agents in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design